Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 7 studies | 38% ± 17% |
Insufficient scRNA-seq data for expression of TRIP13 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 98% | 146.06 | 176 / 180 | 100% | 32.38 | 428 / 430 |
uterus | 98% | 137.64 | 166 / 170 | 99% | 40.55 | 453 / 459 |
skin | 99% | 851.91 | 1785 / 1809 | 96% | 24.63 | 451 / 472 |
breast | 98% | 137.09 | 452 / 459 | 93% | 23.33 | 1038 / 1118 |
stomach | 91% | 130.90 | 327 / 359 | 96% | 24.99 | 274 / 286 |
bladder | 90% | 88.19 | 19 / 21 | 95% | 32.19 | 481 / 504 |
intestine | 86% | 146.82 | 835 / 966 | 97% | 27.52 | 511 / 527 |
lung | 87% | 182.71 | 501 / 578 | 92% | 34.99 | 1063 / 1155 |
esophagus | 74% | 227.08 | 1069 / 1445 | 98% | 41.83 | 180 / 183 |
kidney | 99% | 143.45 | 88 / 89 | 32% | 3.14 | 289 / 901 |
pancreas | 62% | 41.47 | 204 / 328 | 66% | 9.46 | 117 / 178 |
adrenal gland | 96% | 93.92 | 247 / 258 | 22% | 3.40 | 51 / 230 |
prostate | 90% | 81.13 | 221 / 245 | 26% | 2.45 | 131 / 502 |
brain | 73% | 91.20 | 1932 / 2642 | 42% | 6.26 | 296 / 705 |
tonsil | 0% | 0 | 0 / 0 | 100% | 34.72 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 17.30 | 1 / 1 |
spleen | 100% | 250.57 | 240 / 241 | 0% | 0 | 0 / 0 |
adipose | 98% | 117.96 | 1174 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 24.70 | 28 / 29 |
thymus | 71% | 45.44 | 462 / 653 | 15% | 2.60 | 90 / 605 |
blood vessel | 74% | 53.65 | 983 / 1335 | 0% | 0 | 0 / 0 |
liver | 35% | 39.36 | 80 / 226 | 37% | 4.98 | 150 / 406 |
peripheral blood | 57% | 459.73 | 527 / 929 | 0% | 0 | 0 / 0 |
muscle | 38% | 23.77 | 307 / 803 | 0% | 0 | 0 / 0 |
heart | 34% | 25.40 | 294 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 29% | 2.08 | 23 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0007130 | Biological process | synaptonemal complex assembly |
GO_0007283 | Biological process | spermatogenesis |
GO_0006302 | Biological process | double-strand break repair |
GO_0007131 | Biological process | reciprocal meiotic recombination |
GO_0007141 | Biological process | male meiosis I |
GO_0001556 | Biological process | oocyte maturation |
GO_0051598 | Biological process | meiotic recombination checkpoint signaling |
GO_0007144 | Biological process | female meiosis I |
GO_0007094 | Biological process | mitotic spindle assembly checkpoint signaling |
GO_0048477 | Biological process | oogenesis |
GO_0007286 | Biological process | spermatid development |
GO_0005694 | Cellular component | chromosome |
GO_0001673 | Cellular component | male germ cell nucleus |
GO_0005634 | Cellular component | nucleus |
GO_0042802 | Molecular function | identical protein binding |
GO_0003712 | Molecular function | transcription coregulator activity |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
GO_0016887 | Molecular function | ATP hydrolysis activity |
Gene name | TRIP13 |
Protein name | Pachytene checkpoint protein 2 homolog (Human papillomavirus type 16 E1 protein-binding protein) (16E1-BP) (HPV16 E1 protein-binding protein) (Thyroid hormone receptor interactor 13) (Thyroid receptor-interacting protein 13) (TR-interacting protein 13) (TRIP-13) Pachytene checkpoint protein 2 homolog (TR-interacting protein 13) (TRIP-13) (Thyroid hormone receptor interactor 13) (Thyroid receptor-interacting protein 13) |
Synonyms | PCH2 |
Description | FUNCTION: Plays a key role in chromosome recombination and chromosome structure development during meiosis. Required at early steps in meiotic recombination that leads to non-crossovers pathways. Also needed for efficient completion of homologous synapsis by influencing crossover distribution along the chromosomes affecting both crossovers and non-crossovers pathways. Also required for development of higher-order chromosome structures and is needed for synaptonemal-complex formation. In males, required for efficient synapsis of the sex chromosomes and for sex body formation. Promotes early steps of the DNA double-strand breaks (DSBs) repair process upstream of the assembly of RAD51 complexes. Required for depletion of HORMAD1 and HORMAD2 from synapsed chromosomes (By similarity). Plays a role in mitotic spindle assembly checkpoint (SAC) activation . . FUNCTION: Plays a key role in chromosome recombination and chromosome structure development during meiosis. Required at early steps in meiotic recombination that leads to non-crossovers pathways. Also needed for efficient completion of homologous synapsis by influencing crossover distribution along the chromosomes affecting both crossovers and non-crossovers pathways. . |
Accessions | ENST00000513435.1 H0YAL2 ENST00000166345.8 [Q15645-1] Q15645 |